MARKET

PBMWW

PBMWW

PSYENCE BIOMEDICAL LTD
NASDAQ
0.0221
-0.0027
-10.89%
Closed 14:18 05/14 EDT
OPEN
0.0203
PREV CLOSE
0.0248
HIGH
0.0228
LOW
0.0203
VOLUME
5.01K
TURNOVER
--
52 WEEK HIGH
0.0867
52 WEEK LOW
0.0110
MARKET CAP
--
P/E (TTM)
-0.0011
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 1d ago
Prestige Consumer Healthcare Announces agreement To Acquire LaCorium Health, A Leader In Australian Therapeutic Skin Care For ~150M
Benzinga · 1d ago
Weekly Report: what happened at PBM last week (0504-0508)?
Weekly Report · 3d ago
Weekly Report: what happened at PBM last week (0427-0501)?
Weekly Report · 05/04 10:28
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 05/01 12:05
Weekly Report: what happened at PBM last week (0420-0424)?
Weekly Report · 04/27 10:31
Psyence BioMed begins Phase IIb dosing of NPX-5 in adjustment disorder trial
PUBT · 04/24 06:37
Psyence amends amalgamation agreement with GoldCoast Resource Corp
PUBT · 04/24 06:05
More
About PBMWW
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.

Webull offers Psyence Biomedical Ltd stock information, including NASDAQ: PBMWW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PBMWW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PBMWW stock methods without spending real money on the virtual paper trading platform.